Tesamorelin and visceral fat research
It is a GHRH analog with an FDA-approved indication — but that approval covers one use in one group of people.
TL;DR
- Tesamorelin (brand name Egrifta) is FDA-approved only for reducing excess abdominal fat in adults with HIV and lipodystrophy — not for general body composition or weight management.
- Randomized controlled trials in adults with HIV and lipodystrophy showed statistically significant reductions in visceral adipose tissue (VAT) compared to placebo.
- Other uses are not approved and not established.
What it is
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) — a 44-amino-acid peptide that the hypothalamus naturally produces to stimulate pituitary GH release. The FDA approved tesamorelin in 2010 under the brand name Egrifta for a specific indication: reducing excess abdominal fat in adults with HIV who develop lipodystrophy — a condition in which antiretroviral therapy redistributes fat in problematic ways. Other uses are not approved and have not been established. It is not an approved therapy for general abdominal fat reduction.
How it works
Tesamorelin binds GHRH receptors on pituitary somatotroph cells, prompting them to release growth hormone. Elevated GH in turn stimulates IGF-1 production in the liver. GH has known lipolytic effects — it promotes the breakdown of fat, particularly visceral adipose tissue, which surrounds abdominal organs. Visceral fat is metabolically distinct from subcutaneous fat and is associated in epidemiological literature with higher cardiovascular risk. The proposed mechanism for the fat reduction seen in the HIV trials is that GH-axis stimulation shifts substrate utilization.
Who asks about it
People come to tesamorelin typically after reading that it has a formal FDA approval (which is unusual for GHRH analogs) and wanting to understand whether it applies to general body composition goals. It is not approved for that, and that use has not been established. It also comes up in conversations about visceral fat specifically, as opposed to subcutaneous fat — because they respond to different interventions in the research literature.
What the research says
A pivotal randomized controlled trial published in the New England Journal of Medicine (Falutz et al., 2007) enrolled 412 adults with HIV-associated lipodystrophy. Participants receiving tesamorelin showed a statistically significant reduction in visceral adipose tissue vs. placebo — a 15.2% mean reduction — at 26 weeks. IGF-1 levels rose significantly. Later reports from the same research program described similar findings. Notably, in the extension study, VAT reduction was not maintained after tesamorelin was stopped. Benefits outside the HIV-lipodystrophy population have not been established.
What to know
Supraphysiologic IGF-1 elevation carries potential risks, including fluid retention, joint discomfort, and — in the longer-term literature — questions about IGF-1's relationship to certain cancer cell growth that remain under investigation. Outside its one approved use, tesamorelin is not an established treatment.
The Halftime POV
Tesamorelin has something most GHRH analogs lack: Phase III trial data in a defined human population. But that evidence comes from adults with HIV and lipodystrophy, and the approval covers only that use. For anyone else concerned about visceral fat, these trials do not make tesamorelin an option. The research is worth understanding; so is the context in which it was generated.
Related reading:
FAQ
Q: What is tesamorelin? A: Tesamorelin (brand name Egrifta) is a synthetic GHRH analog — it mimics growth-hormone-releasing hormone to stimulate pituitary GH secretion. It is FDA-approved for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. It is the only GH-axis compound with FDA approval for a visceral fat indication.
Q: What does published research show about tesamorelin and visceral fat? A: Randomized controlled trials in patients with HIV-associated lipodystrophy documented significant reductions in visceral adipose tissue compared to placebo. The trials measured visceral fat by abdominal CT and showed statistically significant reductions at 26 weeks. These findings apply to the specific population studied — HIV patients with lipodystrophy. Other uses have not been established.
Q: Is tesamorelin approved for general use? A: No. Tesamorelin's approval, as the brand drug Egrifta, covers one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Other uses are not approved and not established. Compounded tesamorelin is not FDA-approved.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Falutz J et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." — N Engl J Med, 2007
- Tesamorelin (Egrifta) — FDA Prescribing Information, 2010
- Falutz J et al. "Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation." — AIDS, 2008
Frequently asked questions
What is tesamorelin?
Tesamorelin (brand name Egrifta) is a synthetic GHRH analog — it mimics growth-hormone-releasing hormone to stimulate pituitary GH secretion. It is FDA-approved for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. It is the only GH-axis compound with FDA approval for a visceral fat indication.
What does published research show about tesamorelin and visceral fat?
Randomized controlled trials in patients with HIV-associated lipodystrophy documented significant reductions in visceral adipose tissue compared to placebo. The trials measured visceral fat by abdominal CT and showed statistically significant reductions at 26 weeks. These findings apply to the specific population studied — HIV patients with lipodystrophy. Other uses have not been established.
Is tesamorelin approved for general use?
No. Tesamorelin's approval, as the brand drug Egrifta, covers one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Other uses are not approved and not established. Compounded tesamorelin is not FDA-approved.
